Elucidating the Clinical Implications and Pathophysiology of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction: A Call to Action: A Science Advisory from the American Heart Association

Evan L. Brittain, Thenappan Thenappan, Jessica H. Huston, Vineet Agrawal, Yen Chun Lai, Debra Dixon, John J. Ryan, Eldrin F. Lewis, Margaret M. Redfield, Sanjiv J. Shah, Bradley A. Maron

Research output: Contribution to journalReview articlepeer-review

Abstract

This science advisory focuses on the need to better understand the epidemiology, pathophysiology, and treatment of pulmonary hypertension in patients with heart failure with preserved ejection fraction. This clinical phenotype is important because it is common, is strongly associated with adverse outcomes, and lacks evidence-based therapies. Our goal is to clarify key knowledge gaps in pulmonary hypertension attributable to heart failure with preserved ejection fraction and to suggest specific, actionable scientific directions for addressing such gaps. Areas in need of additional investigation include refined disease definitions and interpretation of hemodynamics, as well as greater insights into noncardiac contributors to pulmonary hypertension risk, optimized animal models, and further molecular studies in patients with combined precapillary and postcapillary pulmonary hypertension. We highlight translational approaches that may provide important biological insight into pathophysiology and reveal new therapeutic targets. Last, we discuss the current and future landscape of potential therapies for patients with heart failure with preserved ejection fraction and pulmonary vascular dysfunction, including considerations of precision medicine, novel trial design, and device-based therapies, among other considerations. This science advisory provides a synthesis of important knowledge gaps, culminating in a collection of specific research priorities that we argue warrant investment from the scientific community.

Original languageEnglish (US)
Pages (from-to)E73-E88
JournalCirculation
Volume146
Issue number7
DOIs
StatePublished - Aug 16 2022

Bibliographical note

Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.

Keywords

  • AHA Scientific Statements
  • heart failure
  • hypertension, pulmonary

PubMed: MeSH publication types

  • Journal Article
  • Review

Fingerprint

Dive into the research topics of 'Elucidating the Clinical Implications and Pathophysiology of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction: A Call to Action: A Science Advisory from the American Heart Association'. Together they form a unique fingerprint.

Cite this